About Roivant

We develop transformative medicines and technologies by building agile, focused companies called Vants.

Why We're Here

Roivant was founded in 2014 with the goal of developing and delivering medicines to patients faster and more efficiently

01

Roivant has built 20+ portfolio companies (Vants)

Our Vants have conducted 9 Phase 3 trials (the last 8 of which have been successful), and launched VTAMA®, (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults

02

$3B Upfront Strategic Transaction

In 2019, we consummated a $3B upfront strategic transaction with our partners at Sumitomo Pharma, and we have continued to build a broad and differentiated pipeline of drugs and drug candidates

03

Diverse leadership and employee base

We have worked to ensure an open, diverse, and inclusive culture, while building a leadership team, board of directors and broader employee base that reflects these values.

Our vant creation Process:

Our vant creation Process
Leadership

Roivant empowers a global team of innovators from within and beyond the biopharmaceutical industry to tackle the most pressing challenges in healthcare today.

Matt Gline

Matt Gline

Chief Executive Officer

Plus Sign

Eric Venker, MD

Eric Venker, MD

President & Chief Operating Officer

Plus Sign

Mayukh Sukhatme, MD

Mayukh Sukhatme, MD

President & Chief Investment Officer

Plus Sign

Frank Torti, MD

Frank Torti, MD

Vant Chair

Plus Sign

Amy Mahery

Amy Mahery

Chief Commercial Officer

Plus Sign

Srini Ramanathan, PhD

Srini Ramanathan, PhD

Chief Development Officer

Plus Sign

Richard Pulik

Richard Pulik

Chief Financial Officer

Plus Sign

Rakhi Kumar

Rakhi Kumar

Chief Accounting Officer

Plus Sign

Jo Chen

Jo Chen

General Counsel

Plus Sign

Matt Maisak, PhD

Matt Maisak, PhD

Chief Operating Officer, Roivant Platforms

Plus Sign

Alex Gasner

Alex Gasner

EVP, Roivant Health

Plus Sign

Kelly Graff

Kelly Graff

Head of People

Plus Sign

Vivek Ramaswamy

Vivek Ramaswamy

Chairman

Plus Sign

Melissa Epperly

Melissa Epperly

Director

Plus Sign

Ilan Oren

Ilan Oren

Director

Plus Sign

Daniel Gold

Daniel Gold

Director

Plus Sign

Hiroshi Nomura

Hiroshi Nomura

Director

Plus Sign

James Momtazee

James C. Momtazee

Director

Plus Sign

Keith Manchester

Keith Manchester

Director

Plus Sign

Ivan Cornella Taracido

Iván Cornella-Taracido, PhD

Vice President of Translational Chemical Biology

Plus Sign

Huafeng Xu

Huafeng Xu, PhD

Chief Technology Officer

Plus Sign

Eric Valeur

Eric Valeur, PhD

Vice President, Head of Drug Discovery

Plus Sign

Jason Imbriglio

Jason Imbriglio, PhD

Vice President, Discovery Chemistry

Plus Sign

Tudor Oprea

Tudor Oprea, MD, PhD

Vice President, Translational Informatics

Plus Sign

Cellular Background

10

or more pivotal or pivotal-enabling trials expected by the end of calendar year 2022


We have a diverse pipeline of investigational drugs across our family of companies.


For Investors
For Investors

Learn more about our work

Sign up for our latest announcements and upcoming presentations

Pipeline
Pipeline

Advancing medicines that matter

View our broad and differentiated pipeline of investigational drugs.

Our Science
Our Science

Designing better molecules, atom by atom

Learn about our work in heterobifunctionals, covalency and designing best-in-class small molecules.